Sudubrilimab

Sudubrilimab Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 021-61312847; 18021002903
Email: 3008007409@qq.com
Products Intro: Product Name:Sudubrilimab (anti-PD-L1)
CAS:2387417-06-1
Package:5mg;10mg Remarks:K14633
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Sudubrilimab
CAS:2387417-06-1
Purity:95% Package:100ug;500ug;1mg
Company Name: Guangzhou Hongyuan Chemical Co.,Ltd  
Tel: 15817493340
Email: 981810490@qq.com
Products Intro: Product Name:Sudubrilimab
CAS:2387417-06-1
Purity:95% Package:1mg;1g;100g
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Sudubrilimab
CAS:2387417-06-1
Purity:>95% Package:100ug;200ug;1mg
Company Name: Biolab Reagents  
Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Products Intro: Product Name:Research Grade Sudubrilimab (DHJ70116)
CAS:2387417-06-1
Purity:PAGE:>95% Package:100ug;1mg
Sudubrilimab Basic information
Product Name:Sudubrilimab
Synonyms:Sudubrilimab;Research Grade Sudubrilimab (DHJ70116);Research Grade Sudubrilimab;Sudubrilimab (anti-PD-L1)
CAS:2387417-06-1
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Sudubrilimab Structure
Sudubrilimab Chemical Properties
Safety Information
MSDS Information
Sudubrilimab Usage And Synthesis
UsesSudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment[1].
References[1] Gao ZZ, et, al. Optimization strategies for expression of a novel bifunctional anti-PD-L1/TGFBR2-ECD fusion protein. Protein Expr Purif. 2022 Jan;189:105973. DOI:10.1016/j.pep.2021.105973
Sudubrilimab Preparation Products And Raw materials
Tag:Sudubrilimab(2387417-06-1) Related Product Information
Gimsilumab Amivantamab Cabiralizumab Tirnovetmab Lorigerlimab Quisovalimab Pozelimab Apitegromab Glenzocimab Zimberelimab